Letrozole Accord

Letrozole, the active ingredient in Letrozole Accord, is a aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can stimulate tumor growth.

GNH USA supplies Letrozole Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets. The product conforms to EU pharmacopeial standards and is available for bulk procurement internationally.

Letrozole acts on estrogen‑dependent pathways and is indicated for the following breast‑cancer indications.

- Hormone receptor‑positive metastatic breast cancer: reduces disease progression and improves survival. - Hormone receptor‑positive early‑stage breast cancer (adjuvant setting): lowers risk of recurrence after surgery. - Hormone receptor‑positive postmenopausal breast cancer (neoadjuvant therapy): shrinks tumors prior to definitive surgery.

Letrozole may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hot flashes - Joint pain - Fatigue - Nausea

Serious or Rare Side Effects: - Severe liver injury - Osteoporotic fractures - Pulmonary embolism

When prescribing Letrozole, clinicians should observe several safety measures.

- Bone health monitoring: assess bone mineral density periodically. - Liver function: check hepatic enzymes before initiating therapy and during treatment. - Lipid profile: monitor cholesterol levels regularly. - Pregnancy avoidance: contraindicated in pregnant or breastfeeding women. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Letrozole can interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract letrozole’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): letrozole may enhance anticoagulant effect, requiring INR monitoring. - Tamoxifen: combined use can diminish therapeutic benefit of both agents. - Diuretics: may increase risk of electrolyte disturbances, especially hypokalemia.